{'fraction_non_alphanumeric': 0.02874251497005988, 'fraction_numerical': 0.019161676646706587, 'mean_word_length': 4.887323943661972, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Recommended dose of alfacacidol for osteoporosis.

The present study aims to investigate a proper dose of alfacalcidol by using the parathyroid level as a marker due to the end product of alfacalcidol is calcitriol which has a property of suppression secretion of parathyroid glands. The research enrolled 259 volunteers which were divided into 2 groups. Each group took the elemental calcium 800 milligram plus alfacalcidol at the different doses. Group (A) received alfacalcidol 1.0 microgram/day and Group (B) had alfacalcidol 1.5 micrograms/day for 3 months. Group (A) could not suppress the secretion of PTH compared with Group (B) of which the PTH level was decreased significantly (p = 0.047). Alfacalcidol in both groups can not decrease the bone resorption monitored by using the bone resorption marker, BetacrossLaps or bCTx.